- Package
- 1 mg
- Purity
- 98%
- Price
- Request review
- Availability
- Shipping review required
- Delivery
- Shipping review required
CAS Number: 1693766-04-9
Submit an RFQ to review pricing, availability, lead time, pack size, purity, COA, and supplier SDS for this catalog entry.
Available options
Shipping review is required before pricing or stock can be confirmed publicly. Shipping, duties, and documentation fees are confirmed before order acceptance.
CAS Number
1693766-04-9
PubChem CID
121230107
Molecular Formula
C20H21NO3
Molecular Weight
323.4 g/mol
Exact Mass
323.152144
InChIKey
QQBGNWWJANJWNY-UHFFFAOYSA-N
SMILES String
CCCOc1ccn2c(C(C)=O)cc(-c3cccc(OC)c3)c2c1
No physical property values available.
Properties are provided as catalog reference data and may be confirmed through supplier documentation when required.
Structural features
1-[1-(3-Methoxyphenyl)-7-propoxyindolizin-3-yl]ethanone (CAS 1693766-04-9) is listed in the Pharmaceutical Intermediates portfolio, with molecular formula C20H21NO3 and molecular weight 323. 40 g/mol.
Sourcing context
Catalog reference for RFQ preparation, supplier confirmation, and research chemical sourcing review.
Research use context
Intended for research-stage medicinal chemistry and intermediate synthesis workflows; structure-derived tags include nitrogen-containing heterocycle.
Documentation needs
COA/SDS status, availability, lead time, pack size, and shipment documentation can be confirmed during quotation.
ChEMBL reports experimental activity evidence for: Bromodomain-containing protein 9 (Homo sapiens) — 6 assays; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 (Homo sapiens) — 2 assays; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4 (Homo sapiens) — 2 assays; Bromodomain adjacent to zinc finger domain protein 2A (Homo sapiens) — 3 assays; Bromodomain adjacent to zinc finger domain protein 2B (Homo sapiens) — 2 assays. These records describe research assays and do not establish therapeutic efficacy or clinical use.
Bromodomain-containing protein 9
Homo sapiens · SINGLE PROTEIN · 6 qualifying assays · 3 documents · best pChEMBL 5.98
Experimental evidence source: ChEMBL
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2
Homo sapiens · SINGLE PROTEIN · 2 qualifying assays · 2 documents · best pChEMBL 4.8
Experimental evidence source: ChEMBL
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4
Homo sapiens · SINGLE PROTEIN · 2 qualifying assays · 2 documents · best pChEMBL 4.8
Experimental evidence source: ChEMBL
Bromodomain adjacent to zinc finger domain protein 2A
Homo sapiens · SINGLE PROTEIN · 3 qualifying assays · 3 documents
Experimental evidence source: ChEMBL
Bromodomain adjacent to zinc finger domain protein 2B
Homo sapiens · SINGLE PROTEIN · 2 qualifying assays · 2 documents
Experimental evidence source: ChEMBL
Safety and handling reference content is available through documentation requests.
For supplier-issued SDS, request documentation before handling, storage, shipment, or procurement decisions.
Preliminary Safety Reference
For supplier-issued SDS or COA, submit a documentation request.
Safety Reference / SDS RequestCatalog navigation
Other public CAS pages in this catalog. These links support navigation across additional intermediates and do not imply equivalence, availability, or shared use.
1-[1-(3-Methoxyphenyl)-7-propoxyindolizin-3-yl]ethanone is identified by CAS 1693766-04-9, with molecular formula C20H21NO3, molecular weight 323.4, InChIKey QQBGNWWJANJWNY-UHFFFAOYSA-N.
ChEMBL contains qualifying experimental assay evidence associated with Bromodomain-containing protein 9, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4, Bromodomain adjacent to zinc finger domain protein 2A, Bromodomain adjacent to zinc finger domain protein 2B. These records do not establish therapeutic efficacy or clinical use.
Yes. Submit an RFQ and specify COA requirements. Lot-specific COA depends on supplier confirmation.
Yes. Supplier SDS can be requested through the RFQ workflow before handling, storage, shipment, or procurement decisions.
Availability, pack size, lead time, and pricing are confirmed through RFQ.
Submit the CAS number, quantity, purity requirement, and destination country for sourcing review.